Fulcrum

Fulcrum GT to Provide Sponsorship and Education Contributions at ALA’s 2024 Annual Conference & Expo

Retrieved on: 
星期四, 五月 16, 2024
Convention center, Fulcrum, Conference, Methot, Video game

With Fulcrum Snap, clients choose the solutions they need to evolve their firm, from matter inception and execution to business operations, all with real-time analytics.

Key Points: 
  • With Fulcrum Snap, clients choose the solutions they need to evolve their firm, from matter inception and execution to business operations, all with real-time analytics.
  • As part of the conference education program, Fulcrum senior manager of e-billing solutions Kasey Methot will lead the session “Stay Ahead of the Game: E-Billing Is Here.
  • The ALA’s Annual Conference & Expo is the premier event for legal management professionals.
  • This year’s conference, with the theme “Discover the Difference,” is being held at the Gaylord Rockies Resort & Convention Center.

Fulcrum IT Partners’ Verticalized AI Platforms Proven to Help Businesses Accelerate Growth and Solve for Desired Outcomes

Retrieved on: 
星期四, 五月 23, 2024
Carriers and Services, Software, Mobile, Wireless, Networks, Internet, Data Management, Apps, Applications, Technology, Artificial Intelligence, Security, 5G, Other Technology, Telecommunications, QC, Microsoft, ITSM, Fulcrum, CAPEX, Forecasting, Engineering, Ingram Micro, AI, Face, NVIDIA, Quality control, RPA, Customer service

Fulcrum IT Partners, a $1 billion-plus international IT solution provider, announces a differentiated approach to developing and consuming customized AI services, utilizing its applied AI strategy and proprietary verticalized AI platforms.

Key Points: 
  • Fulcrum IT Partners, a $1 billion-plus international IT solution provider, announces a differentiated approach to developing and consuming customized AI services, utilizing its applied AI strategy and proprietary verticalized AI platforms.
  • The suite of services and solutions is purposefully designed to action, integrate, secure, and scale AI for businesses seeking to accelerate their success using the power of AI.
  • Fulcrum’s AI strategy is crafted to bridge the knowledge gap customers face and introduce actionable AI into their businesses to create more efficiency and generate more revenue.
  • Moreover, Fulcrum enables businesses to acquire AI hardware as a service, reducing CAPEX and promoting a more agile IT infrastructure.

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Retrieved on: 
星期四, 五月 9, 2024
Fulcrum, Therapy, Patient, Webcast, Fireside chats, Fireside

ET.

Key Points: 
  • ET.
  • ET.
  • (Fireside Chat)
    The webcast of the presentation will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations .
  • A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

Retrieved on: 
星期三, 五月 8, 2024
Losmapimod, Fulcrum, Abdomen, NDA, The Lancet, Muscle weakness, REACH, Lancet Neurology, Disability, DUX4, Disease, Patient, FSHD, Face, Gene expression, Clinical trial, Therapy, File, Atrophy

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD). The data are published in the peer-reviewed journal The Lancet Neurology.

Key Points: 
  • The data are published in the peer-reviewed journal The Lancet Neurology .
  • No serious adverse events related to the drug were reported, and there were no discontinuations of treatment due to adverse events.
  • In September 2023, Fulcrum announced the enrollment completion for the Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe.
  • The clinical trial remains on track with topline data expected in Q4 2024.

Fulcrum GT Renews Its Commitment to Els for Autism Foundation

Retrieved on: 
星期三, 四月 24, 2024
ELS, Fulcrum, Spectrum, Autism spectrum, HCM, Golf, Günther Hamburg Classics, Organization, Cryptocurrency

The Els for Autism Golf Challenge regional event series is one of the largest charity-driven, amateur golf tournaments.

Key Points: 
  • The Els for Autism Golf Challenge regional event series is one of the largest charity-driven, amateur golf tournaments.
  • “The Els for Autism Foundation is a leader in supporting families affected by autism spectrum disorder, with programs reaching countless beneficiaries in the U.S. and around the globe,” says Fulcrum GT founder and CEO Ahmed Shaaban.
  • “We are thrilled to support the important work of the foundation and look forward to our teams and clients enjoying this year’s Golf Challenge series in the months ahead.”
    The Els for Autism Foundation was established in 2009 by Liezl Els, Ernie Els and Marvin R. Shanken.
  • Els for Autism serves families around the world, providing virtual services and in-person programs and services at the Els Center of Excellence® campus in Jupiter, Florida.

Fulcrum GT Earns Recognition for Innovation and Accelerated Growth

Retrieved on: 
星期五, 四月 5, 2024
Editorial, Culture, Organization, Database, Growth, MIC, Inc., Corporate services, Risk, Gold, AI, Hope, Regionals, Taco Bell, Most, Fast, Geography, Fulcrum

CHICAGO, April 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum GT , provider of the leading digital business platform for legal and professional services firms, is proud to share two recent public rankings recognizing the company for its achievements in innovation and growth.

Key Points: 
  • CHICAGO, April 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum GT , provider of the leading digital business platform for legal and professional services firms, is proud to share two recent public rankings recognizing the company for its achievements in innovation and growth.
  • “The entire team at Fulcrum works hard every day to create and deliver innovative solutions that support the evolving needs of our clients.
  • Inclusion on these rankings is a testament to that effort and to the resulting growth we’ve achieved.
  • Fulcrum earned its rank with a two-year revenue growth from 2020 to 2022 of 197%, while other companies on the 2024 Inc. 5000 Regionals: Midwest list had an average growth rate of 134.06%.

Terra Balcanica Executes Letter of Intent For Option Agreement To Acquire 100% Interest In Advanced Saskatchewan Uranium Portfolio

Retrieved on: 
星期三, 四月 3, 2024
Uranium, Fulcrum, Agreement, Terra, Letter, Option, FRA, News, Acquisition, NSR, National instrument, Mean reversion (finance), MBA, CFA, Legislation, Contract management, AIM, Map

Pursuant to the Agreement, Terra will have an option (the “Option Agreement”) to acquire a 100% interest in Fulcrum’s Charlot-Neely, Fontaine Lake, Snowbird and South Pendleton uranium licences (the “Licences”) located in northern Saskatchewan, Canada and collectively encompassing 596.71 km2 of highly prospective ground for a uranium discovery.

Key Points: 
  • Pursuant to the Agreement, Terra will have an option (the “Option Agreement”) to acquire a 100% interest in Fulcrum’s Charlot-Neely, Fontaine Lake, Snowbird and South Pendleton uranium licences (the “Licences”) located in northern Saskatchewan, Canada and collectively encompassing 596.71 km2 of highly prospective ground for a uranium discovery.
  • Terra Balcanica CEO, Dr. Aleksandar Mišković, commented: “In our pursuit of high-quality assets worldwide, Terra Balcanica has secured an option to acquire a Canadian uranium portfolio covering close to 600 km2 with tremendous potential for discovery.
  • In a world transitioning to green energy solutions, the acquisition of these assets provides a more robust and diverse exploration portfolio for Terra.
  • On closing of the transaction, Terra will have a four-year option to acquire 100% of Fulcrum’s owned uranium licences.

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium

Retrieved on: 
星期四, 三月 28, 2024
Webcast, Patient, Therapy, Fulcrum

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m.

Key Points: 
  • CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m.
  • ET.
  • The webcast of the presentation will be accessible here and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations .
  • A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
星期五, 三月 22, 2024
Patient, Employment, Therapy, Fulcrum

CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer.

Key Points: 
  • CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer.
  • Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Fulcrum granted Dr. Horn a non-statutory option to purchase 400,000 shares of the company’s common stock, with an exercise price of $10.12 per share, the closing price per share of the company’s common stock as reported by Nasdaq on the grants’ effective date, March 18, 2024.
  • Dr. Horn’s stock option to purchase 400,000 shares of Fulcrum’s common stock has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of Dr. Horn’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the 12 successive quarters following the first anniversary, subject to Dr. Horn’s continued service with the company through the applicable vesting dates.

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
星期一, 三月 18, 2024
Sickle cell disease, University, Medicine, Doctor of Philosophy, Albireo, New Drug Application, Patient, SVP, Research, Losmapimod, Senior, Homocystinuria, Facioscapulohumeral muscular dystrophy, Therapy, DRS, Hereditary angioedema, Drug development, Interim, Boston, Fulcrum, PFIC, DSM-IV codes, Pharmaceutical industry

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately. Dr. Horn is a seasoned executive with over 20 years of end-to-end drug development experience spanning multiple therapeutic areas, with an emphasis on rare diseases, across both large pharmaceutical and biotech companies. Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development. Together, Drs. Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.

Key Points: 
  • Interim chief medical officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as SVP of early development.
  • Horn and Fraser will be responsible for leading clinical development and overseeing regulatory strategy and execution.
  • His most recent role was as the Chief Medical Officer at HemoShear Therapeutics, specializing in rare metabolic diseases.
  • Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.